********IRB Frequently Asked Questions********

Similar documents
The Importance of Following the PROTOCOL in Clinical Trials

12.0 Investigator Responsibilities

Principal Investigator and Sub Investigator Responsibilities

Investigator responsibilities for research conducted under the authority of the UTHSCSA Institutional Review Board (IRB)

Guidance on IRB Continuing Review of Research

Adventist HealthCare, Inc.

IRB Submissions and Human Subjects Research Compliance. Georgia Health Sciences University

IOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others

SAN DIEGO COMMUNITY COLLEGE DISTRICT INSTITUTIONAL REVIEW BOARD (IRB) INVESTIGATOR GUIDELINES FOR RESEARCH USING HUMAN SUBJECTS

CLINICAL RESEARCH ROLES CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

Principal Investigator Responsibilities for Education and Social/Behavioral Researchers

Guidance for IRBs, Clinical Investigators, and Sponsors

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities

This policy applies to all clinical research conducted at Beaumont Health System.

Nova Southeastern University Institutional Review Board Policies and Procedures

STANDARD OPERATING POLICY AND PROCEDURE

WHEN I WANT TO: I NEED TO SUBMIT: {for CIRB studies, see the specific FAQ}

Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues

INVESTIGATOR HANDBOOK

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

EVALUATION BRIEF Understanding the Institutional Review Board (IRB) January 2008

OPERATING PROCEDURES

Standard Operating Procedures

Role of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.

Reliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s)

ROLE OF THE RESEARCH COORDINATOR Study Start-up Best Practices

How To Write A Binder Tab

University of California Davis. Investigator Manual. Revised March 10, 2016

2 Applicability: Effective Date: 1/15/2010 Revised: 8/13/2010, 9/10/10, 5/9/14

Claim of Exemption Form Page 1 of 6

Quality Monitoring Checklist

No Page 1 of 5. Issue Date 4/21/2014

A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky

Guidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB

Documentation of the Informed Consent Process. USC Office for the Protection of Research Subjects (OPRS)

Orientation Manual for Clinical Research Coordinators

INVESTIGATOR MANUAL. Table of Contents

UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM. DoD/DON-funded Research

Comprehensive Study Documents List (Biomedical Studies)

Guidance for Clinical Investigators, Sponsors, and IRBs

Getting Through The Approval Process

Research Coordinator - PI s who have research coordinators or secretarial support can designate individuals to manage their IRB protocols in Mentor.

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)

Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health

Human Subjects Research at OSU

INTERIM SITE MONITORING PROCEDURE

Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs

Instructions for Form: Application for Claim of Exemption

Human Subjects Research (HSR) Series

RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS

Yale University Open Data Access (YODA) Project Procedures to Guide External Investigator Access to Clinical Trial Data Last Updated August 2015

Institutional Review Board

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

The Ontario Cancer Research Ethics Board Overview

Effective Date: October 2015

Clinical Trial Protocol Development. Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group

2. For all clinical trials, the coverage analysis will also be audited to ensure compliance with the Medicare National Coverage Determination.

DHHS/NIH/OD/OIR/OHSRP 1/2/2015

Breast Cancer Registry of Greater Cincinnati (BCRGC) APPLICATION for ACCESS to INFORMATION/DATA

Policy of the National Institute of Nursing Research for Data and Safety Monitoring of Extramural Clinical Trials

Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA Phone:

Children s Research Management System (CRMS) Version 3.0. Children s Hospital Colorado Research Institute Training Guide April 2015

Policy on Human Subject Protection Training, Certification and Recertification at AUB

CHILDREN AND ADULTS SERVICE RESEARCH APPROVAL GROUP

Clinical Trials Reporting Program (CTRP) and Clinicaltrials.gov (CT.gov) Helpful tips and guidance

Academic Honors UF Requirements. Bill Millard, Ph.D. College of Pharmacy University of Florida

IRB 101: HUMAN SUBJECTS PROTECTION PROGRAM

Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.

Evaluation Instrument for Accreditation January 1, 2015

INSTITUTIONAL REVIEW BOARD

Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events

Guide for Research Sites Seeking Accreditation

Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager

CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS:

To IRB, or Not to IRB? That Is the Question!

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute

Regulatory Binder Instructions 25 April 2016

ELECTRONIC W2 CONSENT PROCESS

Clinical Research Professional Certification & Preparing for the CCRP Exam

Investigational Drugs: Investigational Drugs and Biologics

This policy applies to research administrators, investigators, research staff, Human Investigation Committee (HIC) members and HIC staff.

Yale Cancer Center Data and Safety Monitoring Committee Charter

Department of the Navy Human Research Protection Program

Data Safety Monitoring and the IRB. Bertha delanda IRB Training Specialist Research Compliance Office February 2011

UT Health Science Center at San Antonio Research/Grant Records

December 13, 2011 Maureen Coyne

2014 Metrics on Human Research Protection Program Performance

Using Social Media in Research: Regulatory and IRB Considerations

Classifying Adverse Events From Clinical Trials

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS

CLINICAL RESEARCH GENERIC TASK DESCRIPTIONS

PMAs, 510(k)s, and Advanced IDE Topics

Department of Defense Human Research Protection Program AIR FORCE ISSUED DEPARTMENT OF DEFENSE (DOD) INDIVIDUAL INVESTIGATOR AGREEMENT 3/3/2009

USE OF HUMAN SUBJECTS IN RESEARCH PRESENTED BY BRIAN WEIMER TULANE UNIVERSITY RESEARCH COMPLIANCE OFFICER

IRB RESEARCH REPOSITORY COMPLIANCE PROGRAM. Susan Burner Bankowski, MS, JD Chair, OHSU IRB

Clinical Investigator Training Course

Health Products and Food Branch.

The Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis

Transcription:

New Studies How do I know which type of application to complete? How long does it take to get approval for a new study? Amendments What types of changes need IRB review? How do I make a change to my IRB approved study? How long does it take to get approval of an amendment? Continuing Review (progress reports) How to determine when my study expires? When is my progress report due? What is required in my continuing review submission? How does UTHSCSA define an enrolled subject? ********IRB Frequently Asked Questions******** Adverse Events What is the IRB s policy regarding reporting adverse events? Protocol Deviations What do I do with my protocol deviation tracking log? Study Personnel Who needs to be listed as study staff? Informed Consent Do I need to use a consent form that has a stamp on it? I am only enrolling non-english Speaking subjects into my study. Do I have to submit an English consent document for IRB approval? Does the new Clinical Trial statement in the informed consent apply to my research study? Recruitment Material Does the IRB need to review recruitment material for my study? IRB Authority Does my study/project need IRB Review? What is the difference between convened IRB, expedited and exempt review? Why does the IRB need to review my grant? When are IRB meetings and submission deadlines? CITI Training Who needs to have completed CITI Training? How often do I need to re-take the CITI Training? What if I have another type of Human Subjects Protection Training from another program? IRB Fees Does the IRB charge a fee for the review of research? Whose responsibility is it to pay the IRB fee? Will I be charged if the Sponsor withdraws the study after IRB approval but before enrollment begins? My study was tabled by the IRB and the sponsor withdrew the study. Why am I being charged an IRB fee? Who do I contact regarding payment of an IRB fee? Does the IRB charge for each new study, amendment, and progress report? How much is the IRB fee? What method of payment is accepted? Updated 05/24/2016 Page 1 of 16

eprotocol eprotocol was discontinued in August 2012. UTHSCSA staff no longer have access to the IRB section of eprotocol. How do I inquire about a study reviewed under eprotocol? Why can t I login to IRB on eprotocol? PI Self-Assessment Program What is the PI Self-Assessment Program? Who will need to complete an assessment and how often? How will Investigators be notified that they need to complete an assessment? Will the assessment remain anonymous and how will the Investigator receive feedback from the IRB? How long will the investigator have to complete the assessment? What if an investigator does not complete an assessment? Where may I find a sample of the assessment? When did the PI-Self Assessment Program begin? Where to see more information or who to contact with questions regarding the PI Self-Assessment Program? Miscellaneous Where may I find the IRB s e-signature policy in accordance with 21 CFR 11 Electronic Records; Electronic Signatures? Updated 05/24/2016 Page 2 of 16

New Studies How do I know which type of application to complete? It depends on your study design and how much risk is involved in the study. If the study involves: Little to no risk generally Exempt review Minimal risk studies (not involving x-rays or other radiation) - generally Expedited IRB review More than minimal risk studies always Full Board (reviewed by convened IRB) Refer to the OIRB website for examples and application forms How long does it take to get approval for a new study? The turnaround time depends on a variety of factors such as: how well the application was prepared, complexity of the study (needing other committee/institution approvals, etc), PI/coordinator response time to OIRB and IRB questions and concerns, etc. The following are the average turnaround times: Exempt approximately 1-3 weeks Expedited approximately 2-4 weeks Convened IRB approximately 6-8 weeks Updated 05/24/2016 Page 3 of 16

Amendments What types of changes need IRB review? All changes require IRB review unless the change is implemented to eliminate an immediate hazard. How do I make a change to my IRB approved study? You must submit an amendment to the IRB office and receive IRB approval before you may implement any changes (unless your study was determined exempt). To submit an amendment you need to: 1. Complete the amendment form: http://research.uthscsa.edu/irb/amendments.shtml 2. Revise any approved application forms or documents (using tracked changes so the IRB can see what was added/deleted) 3. Sign Form A-1 and scan it (or sign it electronically) 4. Save all forms (amendment form, Form A-1, and any revised forms) and email your submission to IRBMail@uthscsa.edu. How long does it take to get approval of an amendment? Expedited The average turnaround time for an Expedited Amendment is one week. If your amendment is especially simple (changing study staff) you may receive approval in as little as 2 days. If your amendment is extremely complicated (i.e., many changes including new procedures and revised study design), or not completed correctly, approval may take 2 weeks or longer. Convened IRB Full Board amendments submitted within the posted guidepost dates (http://research.uthscsa.edu/irb/dates.shtml) will go to the next appropriate meeting (no more than 34 days after submission). You can expect to learn about the Board s decision within ten days following the meeting Updated 05/24/2016 Page 4 of 16

Continuing Review How to determine when my study expires? The original approval letter provides the study s IRB expiration date. When is my progress report due? The progress report is due 45 days prior to the expiration date. What is required in my continuing review submission? The Progress Report Form and any modified documents in tracked changes (if requesting changes as part of the continuing review) such as the consent forms. Other documents that may be submitted include an Adverse Events log (must be signed by the PI) Protocol Deviation Tracking Log, Sponsor reports or notifications, DSMB report or independent medical monitor report, Form X Conflict of Interest form (if there are changes in COI for any research personnel), publications or meeting proceedings. How does UTHSCSA define an enrolled subject? The IRB considers a subject enrolled in a study when the subject signs a consent document. Any screening or testing done for research purposes to determine subject eligibility should not be conducted prior to the subject agreeing and documenting their consent to participate in the research (except where waiver approved). In cases where the IRB approves a waiver from the requirement for obtaining informed consent and/or a waiver from the requirement for documentation of informed consent, any individual on whom data has been collected should be counted as an enrolled subject. Updated 05/24/2016 Page 5 of 16

Adverse Events What is the IRB s policy regarding reporting adverse events? Events or problems that do not meet criteria are recognized by OHRP and the FDA to not yield information useful to IRBs - often lacking context and detail - often incomplete and unanalyzed - and as such inhibit an IRB s ability to assure the protection of human subjects. The IRB Chair or designated reviewer will return a report to the investigator without being reviewed by the IRB if that report does not meet criteria. In order to meet criteria for prompt reporting, before any other consideration, events or problems must first be analyzed by the local investigator considering the need for substantive action (implementing actions if necessary to eliminate immediate hazard). The first criteria in this analysis must be whether the event or problem is unanticipated (e.g., protocol documentation / not within the frequency and severity expected for population s underlying condition (only protocol documentation for UADE s)). See the policy for remaining criteria and further clarification. If anticipated, reporting is still required but may be in the form of a summary as part of the next progress report sent to the IRB for continuing review. Updated 05/24/2016 Page 6 of 16

Protocol Deviations What do I do with my protocol deviation tracking log? Minor Administrative Protocol Deviations Minor or administrative protocol deviations are defined as those which do not affect the scientific soundness of the research or adversely affect the rights, safety, or welfare of human subjects. A minor or administrative protocol deviation is limited to minor departures from the protocol for a single subject. Examples include: follow up visits that occurred outside the protocol required timeline or blood samples obtained at times close to but not precisely at the time points specified in the protocol. Provide a summary in next year s progress report. Emergency Deviations When a deviation occurs in an emergency situation, such as when a departure from the protocol is required to eliminate apparent immediate hazard to the subject. Examples include: withholding study drug in response to a serious adverse event (actual harm) or to avoid a serious harm (risk of harm) Emergency deviations are always considered Unanticipated Problems Involving Risks to Subjects or Others (UPIRSOs). Submit a Prompt Report and summarize event in next year s progress report. Major, Non Emergent Deviations A planned, major, non-emergent change in the protocol may not be initiated without IRB review and approval. Examples include: any changes to the study design or procedures or changes to study staff or sites). Submit an Amendment request to the IRB before change is made. Updated 05/24/2016 Page 7 of 16

Study personnel Who needs to be listed as study staff? Research team members who will be performing research activities and/or research procedures listed in the protocol Clinical (or commercial) services that involve administering the study interventions being tested or evaluated under the protocol Updated 05/24/2016 Page 8 of 16

Informed Consent Do I need to use a consent form that has a stamp on it? Yes. You must use the most recently IRB approved consent form when enrolling patients. Using the consent document with the IRB stamp allows anyone looking at your records to know you used the most current (accurate) consent form. I am only enrolling non-english Speaking subjects into my study. Do I have to submit an English consent document for IRB approval? Yes. However you have two options regarding the method of approval: o Submit the translated consent as an amendment - You may submit an English consent form at initial submission and receive final approval. Then, after the consent form has been translated, you should submit: the English (stamped) consent document, the translated consent document Form H-1 (translation certification), a completed Amendment form and Form A-1 (signature assurance sheet). In this scenario, you will have two approved (stamped) consent documents for your study (one English and one non-english). o Receive approval of the translated consent at initial approval You should submit the English consent form during initial review and the reviewer will provide you with a PDF version of the English consent with the words IRB Approved for Translation on MM/DD/YY in the background of the document. Once the consent form has been translated, submit the English approved (PDF) consent, the translated consent and Form H-1 to the reviewer to receive final approval. The date on the English PDF consent will be the date used on the Form H-1. You will then only receive one officially stamped consent document for your study (one non-english). (This process is only available for use on Expedited submissions). Does the new Clinical Trial (ClinicalTrials.gov) statement in the informed consent document apply to my research study? Yes if your study is a controlled interventional study of drugs, biological products, or devices subject to FDA regulation and the study was initiated after March 7, 2012 No if your study is a small feasibility device trial measuring feasibility of the device or a Phase I Clinical Trial. Updated 05/24/2016 Page 9 of 16

Recruitment material Does the IRB need to review recruitment material for my study? Recruitment materials will not be stamped by the IRB unless required by the sponsor or institution where it will be posted. Updated 05/24/2016 Page 10 of 16

IRB Authority Does my study/project need IRB Review? All projects that meet the definition of research involving human subjects (as defined by federal regulations) require IRB review. Please review the worksheet to determine whether an activity is human research to determine whether your project requires IRB review. Regulatory and ethical obligations to protect research participants apply, for example, to research that uses: Data from varied research methods including surveys, interviews, and observation Private information, such as medical, family, or employment information, or residual administrative records including earnings, and treatment histories that can be readily identified with individuals, even if the information was not specifically collected for the study in question; Tissue specimens, obtained for routine medical care that would have been discarded if not used for research, or DNA samples, where samples or specimens can be linked to a living individual. What is the difference between convened IRB, expedited and exempt review? Convened IRB Submissions are reviewed by a convened board. Committee members meet to discuss the proposal. The board can recommend approval, approval with changes, disapprove, or table the study. Studies reviewed by the convened IRB are generally are greater than minimal risk. Expedited submissions are reviewed by the IRB Chair or other qualified IRB member. The reviewer evaluates the study for approval. This type of review can be carried out on a study that involves minimal risk and fits into one of 7 expedited categories. The reviewer may exercise all the rights of the convened IRB however, may not disapprove a submission. If the reviewer is unable to make a determination the study will be considered at a convened IRB meeting. Exempt Submissions are reviewed by an OIRB staff member, IRB Chair or other qualified IRB member. The reviewer evaluates the studies for approval. The submissions must fit into one of the categories listed in 45 CFR 46.101(b). The investigator makes the initial decision as to which category the research falls under. The IRB may approve the submission under the requested category. If the study does not meet the requirements of exempt review in the opinion of the IRB, a study must be submitted for a different level of review. Why does the IRB need to review my grant? In the past, numerous instances have been identified in which human subject research described in a grant application differed significantly from how it was described in an IRB application. The grant included important elements (e.g., targeting of vulnerable subjects, additional arms, different doses, etc.) that were ultimately implemented without IRB review and approval. US Department of Health and Human Services (DHHS) regulations at 45 CFR 46.103(f) require that each grant application or proposal for DHHSsupported human subject research be reviewed and approved by the IRB. When are IRB meetings and submission deadlines? There is an IRB meeting once every two weeks. The schedule is at http://research.uthscsa.edu/irb/dates.shtml Updated 05/24/2016 Page 11 of 16

CITI Training Who needs to have completed CITI Training? All investigators and research staff engaged in exempt and non-exempt human research must complete appropriate education in research ethics, human research protections and regulatory policy. How often do I need to re-take the CITI Training? If engaged in research at UTHSCSA, appropriate learner module must be renewed every three years. If engaged in research at the VA, the VA Human Subjects Protection and Good Clinical Practices Course must be renewed every three years. What if I have another type of Human Subjects Protection Training from another program? The other training may only be accepted if the Research Protection Programs Director or IRB Associate Director approves the substitution for all non-exempt research. For Exempt research, the OIRB may accept other research ethics training in lieu of CITI training. Documentation must be obtained, maintained and submitted by the trained individual as necessary to indicate that training was completed (or for refresher training was completed every three years) indicating that the Director or Associate Director determined the education to be appropriate education in research ethics, human research protections and regulatory policy. Updated 05/24/2016 Page 12 of 16

IRB Fees Does the IRB charge a fee for the review of research? Yes. The fee structure is different for UTHSCA and non-uthscsa based research: The IRB charges a fee for UTHSCSA industry-sponsored research (pharmaceutical or device firms and other for-profit entities). The IRB does not charge for UTHSCSA studies with federal, state, institutional or other grant funding or for unfunded studies. The IRB charges a fee for non-uthscsa research regardless of the funding according to the MOU between UTHSCSA and the other institution. Whose responsibility is it to pay the IRB fee? The fee is the responsibility of the investigator. It is the investigator s responsibility to ensure the contract makes allowance for the IRB fee. Will I be charged if the Sponsor withdraws the study after IRB approval but before enrollment begins? Yes. If the study is reviewed by the IRB a fee is charged. My study was tabled by the IRB and the sponsor withdrew the study. Why am I being charged an IRB fee? Review by the IRB is a service, and if the study is reviewed, a fee is charged regardless of the outcome. Who do I contact regarding payment of an IRB fee? Please contact the OIRB office at 210-567-8250. Does the IRB charge for each new study, amendment, and progress report? Yes. See the IRB Review Fees Memorandum for details. How much is the IRB fee? See the IRB Review Fees Memorandum for details. What method of payment is accepted? Invoices may be paid by check or Inter-Departmental Transfers (IDTs). Updated 05/24/2016 Page 13 of 16

eprotocol How do I inquire about a study reviewed under eprotocol? eprotocol was discontinued in August 2012. UTHSCSA staff no longer have access to the IRB section of eprotocol. OIRB retrieved all files from the system and have stored them electronically by eprotocol tracking number and PI name. If you have questions for OIRB about your submission, please do the following Locate your approval letter from eprotocol and reference the eprotocol tracking number when contacting the IRB office. If you do not have your approval letter, locate any communication you have received and reference the eprotocol tracking number with your question to the IRB office. If you cannot locate either of the above items, reference the PI name and title of the study when contacting the IRB office. Why can t I login to eprotocol? eprotocol was discontinued in August 2012. UTHSCSA staff no longer have access to the IRB section of eprotocol. Updated 05/24/2016 Page 14 of 16

PI Self-Assessment Program What is the PI Self-Assessment Program? The PI Self-Assessment Program is part of the IRB s quality improvement activities. The PI selfassessment provides an opportunity to educate investigators and research staff on federal, state, and HSC policies and procedures; assist researchers in assessing their own programs, and assist in identifying areas on which additional education programs may need focus. Who will need to complete an assessment and how often? All investigators will eventually need to complete a survey. Each investigator will need to complete an assessment once every three years. How will Investigators be notified that they need to complete an assessment? Investigators are notified two ways. The first notification will be in the initial notice to investigators that a progress report is due from the OIRB. The second notice will come from the Department of Epidemiology and Biostatistics (DEB) providing the investigator with the information necessary access the assessment in the Informatics Data Exchange and Acquisition System (IDEAS). Will the assessment remain anonymous and how will the Investigator receive feedback from the IRB? To ensure the integrity of the data obtained from the investigators, the Office of the IRB will have an independent third party, the DEB, send username and password along with a link to IDEAS for each investigator. If the PI already has an IDEAS username and password set up, the investigator will be asked to use that information to access the assessment. Each assessment will be assigned an identification number. Completed assessments will be stored in IDEAS with the identification number. The assumption is that the PIs may be more comfortable completing an anonymous assessment and more likely to be forthcoming with the requested information. Based upon assessment responses, the OIRB staff will create individualized feedback for each completed assessment. This is aimed to assist the investigator with making the necessary improvements and/or corrections. Feedback reports are stored in IDEAS. The investigator will receive notification when a feedback report is available for review. How long will the investigator have to complete the assessment? Investigators are expected to complete the assessment within two weeks of notification. What if an investigator does not complete an assessment? The OIRB will run a report in IDEAS to determine names of investigators who have not completed the assessment. OIRB Staff will contact to those investigators and plan for completion of the assessment. Where may I find a sample of the assessment? You may find a sample of the assessment on the IRB s website: http://research.uthscsa.edu/irb/miscforms.shtml Updated 05/24/2016 Page 15 of 16

When did the PI-Self Assessment Program begin? April 2, 2012 Where to see more information or who to contact with questions regarding the PI Self- Assessment Program? PI Self Assessment Program Policy and Procedure: http://research.uthscsa.edu/irb/sop.shtml#self_assess OIRB office 210-567-8250 Miscellaneous Where may I find the IRB s e-signature policy in accordance with 21 CFR 11 Electronic Records; Electronic Signatures? The UTHSCSA IRB s use of electronic signature is not subject to part 11 because the electronic signatures we use meet the FDA s definition of a flattened digital signature. As a result, our use of these signatures falls into the realm of use of computers to generate paper printouts of electronic records, and those paper records meet all the requirements of the applicable predicate rules and persons rely on the paper records to perform their regulated activities. Thus, our limited use of digital signatures on our documents that can be printed is not generally considered to be "using electronic records in lieu of paper records" under 11.2(a) and 11.2(b). In these instances, the use of computer systems in the generation of paper records would not trigger part 11 by the FDA. For more information: http://www.fda.gov/regulatoryinformation/guidances/ucm125067.htm Updated 05/24/2016 Page 16 of 16